US FDA approves fidaxomicin for the treatment of Clostridium difficile-zssocm.tA diarrhea

摘要

the US FDA approval of fidaxomicin (DIFICID?) for the treatment of Clostridium difficile associated-diarrhea (CDAD) in adults aged 18 years or older, making it the first antibacterial indicated for the disease to be approved by the FDA in nearly 30 years. Fidaxomicin is the first in a new class of antibiotics termed macrocycles that function by rapidly killing C. difficile by inhibiting the bacterial enzyme RNA polymerase. It is estimated that CDAD may affect more than 700,000 people in the USA each year; however, as many cases are believed to be undiagnosed, untreated and under-reported, the incidence may in fact be higher, "CDAD is a serious illness that can be incredibly disruptive to patients' lives," Kathleen Mullane, Associate Professor of Medicine, Section of Infectious Diseases and Global Health, University of Chicago (IL, USA) explained to Future Microbiology.